Jacobs Levy Equity Management Inc. Invests $40.99 Million in Danaher Corporation $DHR

Key Points

• Jacobs Levy Equity Management Inc. purchased a new stake in Danaher Corporation valued at approximately $40.99 million, acquiring 199,953 shares during the first quarter.
• Insider trading was noted, with Director Teri List selling 2,778 shares at an average price of $211.06, which represents an 11.81% reduction in ownership.
• Wall Street analysts remain optimistic, with a consensus rating of "Moderate Buy" and an average price target of $246.35 for Danaher stock.

Jacobs Levy Equity Management Inc. purchased a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 199,953 shares of the conglomerate's stock, valued at approximately $40,990,000.

Other large investors also recently bought and sold shares of the company. GHP Investment Advisors Inc. increased its position in shares of Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares during the last quarter. Heck Capital Advisors LLC purchased a new stake in shares of Danaher in the 4th quarter valued at approximately $27,000. Sierra Ocean LLC increased its position in shares of Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after purchasing an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Danaher in the 1st quarter valued at approximately $31,000. Finally, Dunhill Financial LLC increased its position in shares of Danaher by 68.4% in the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after purchasing an additional 67 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insider Transactions at Danaher

In related news, Director Teri List sold 2,778 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director owned 20,751 shares in the company, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 11.10% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on DHR shares. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research report on Tuesday, September 2nd. Barclays reissued an "overweight" rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. UBS Group dropped their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Robert W. Baird increased their target price on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research report on Friday, July 18th. Finally, Evercore ISI dropped their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Seventeen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Danaher currently has an average rating of "Moderate Buy" and an average target price of $246.35.

Danaher Stock Performance

NYSE:DHR traded up $2.41 during trading hours on Thursday, reaching $195.00. 1,033,776 shares of the company's stock were exchanged, compared to its average volume of 4,127,595. The firm has a market capitalization of $139.63 billion, a price-to-earnings ratio of 41.50, a P/E/G ratio of 2.71 and a beta of 0.75. The company has a 50-day moving average of $201.62 and a 200 day moving average of $199.15. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. Danaher's quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's payout ratio is 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.